* Alimera Sciences Inc ALIM.OQ ALIM.O is expected to show a
rise in quarterly revenue when it reports results on July 30
(estimated).
* The Alpharetta, Georgia-based company is expected to report
a 59.8% increase in revenue to $16.04 million from $10.04
million a year ago, according to the mean estimate from 3
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Alimera Sciences Inc is
for earnings of $1.06 per share. For the same quarter last year,
the company reported a loss of 51 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the
last three months.
* Wall Street's median 12-month price target for Alimera
Sciences Inc is $16.25, about 46.4% above its last closing
price of $8.71.
* Previous quarterly performance (using preferred earnings
measure in US dollars).
QUARTER STARMINE REFINITIV ACTUAL BEAT, SURPRI
ENDING SMARTESTIM IBES MET, SE %
ATE® ESTIMATE MISSED
Mar. 31 2021 -0.52 -0.54 -0.63 Missed -16.7
Dec. 31 2020 -0.04 -0.04 -0.18 Missed -315.4
Sep. 30 2020 -0.44 -0.44 -0.12 Beat 72.9
Jun. 30 2020 -1.09 -1.61 -0.51 Beat 68.4
Mar. -0.44 -0.43 -0.24 Beat 44.5
31 2020
Dec. 31 2019 -0.35 -0.45 0.08 Beat 117.7
Sep. 30 2019 -0.57 -0.60 -0.60 Met 0
Jun. 30 2019 -0.55 -0.55 -1.05 Missed -90.9
This summary was machine generated July 30 at 02:50 GMT. All
figures in US dollars unless otherwise stated